ChomiX Biotech, a Nanjing, China-based biotechnology company focusing on the preclinical development of innovative small molecule drugs, raised an undisclosed amount in Series Pre-A+ funding.
The round saw participation from TigerYeah Capital, old shareholder Tsinghua Innovation Ventures, and Morning Spring Venture.
The company intends to use the funds to further develop its chemoproteomics platforms, expand covalent compound libraries, and initiate several screening projects against traditionally undruggable targets.
Led by Nan Chen Ph.D., CEO and Founder, ChomiX Biotech is a biotechnology company focusing on the preclinical development of innovative small molecule drugs. With chemoproteomics as the core technology, it is engaged in the discovery of novel lead compounds and protein targets in living cells. Officially operated in 2021, the company has established multiple intersecting platforms, including chemical biology, bioinformatics, medicinal chemistry, molecular and cell biology, etc. Now it has been authorized numbers of chemoproteomics related patents and built a laboratory with a variety of advanced instruments.
ChomiX has partnered with many innovative small molecule drug R&D companies, including PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725), and research institutes.
FinSMEs
15/05/2023